<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421342</url>
  </required_header>
  <id_info>
    <org_study_id>576</org_study_id>
    <nct_id>NCT01421342</nct_id>
  </id_info>
  <brief_title>VA Augmentation and Switching Treatments for Improving Depression Outcomes</brief_title>
  <acronym>VAST-D</acronym>
  <official_title>CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose is to determine research based 'next-steps' for outpatients with major
      depressive disorder who have not had satisfactory outcomes to standard 'first-step'
      treatments. The primary objective is to compare the acute (up to 12 weeks) treatment
      effectiveness of augmenting an antidepressant with aripiprazole or with bupropion-slow
      release (SR) vs. switching treatment to bupropion-SR monotherapy on symptom remission in
      Veterans with Major Depressive Disorder (MDD) who have not achieved optimal response after an
      adequate trial on antidepressant (a selective serotonin reuptake inhibitor [SSRI] or
      serotonin and norepinephrine reuptake inhibitor [SNRI] or mirtazapine) monotherapy. The
      secondary objectives are to compare the acute (up to 12 weeks) and long term (up to 36 weeks)
      efficacy, safety, effects on functioning, suicidality, quality of life, anxiety and other
      associated symptoms, costs and cost-effectiveness of each of the three treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of VAST-D is to enhance treatment outcomes for representative outpatients
      diagnosed with nonpsychotic major depressive disorder (MDD) and treated in primary or
      psychiatric VA care settings. In particular, VAST-D is designed to determine the comparative
      effectiveness of different treatment options for participants with MDD who fail to have a
      satisfactory outcome to treatment with their initial antidepressants.

      These options may be conceptualized as representing two overall treatment strategies: 1)
      Medication Switch - switching from the initial antidepressant to another antidepressant
      medication, specifically bupropion-SR and 2) Medication Augmentation - augmenting the initial
      antidepressant with a second antidepressant, specifically bupropion-SR or a second generation
      antipsychotic, specifically aripiprazole. VAST-D's primary goal is to determine which of
      these 3 treatment strategies is most likely to lead to remission. Other key objectives
      include comparisons of response, time to remission, time to response, relapse, anxiety
      symptoms, suicidal ideation and behaviors, side effects, tolerability, quality of life,
      health related costs and satisfaction with participation in the study.

      VAST-D will enroll 1518 total patients of both genders and all ethnic/racial and
      socioeconomic backgrounds. All patients will meet Diagnostic and Statistical Manual of Mental
      Disorders (DSM)-IV-TR (text revised) criteria for nonpsychotic MDD. The diagnostic criteria
      for eligibility will be established by clinical interview supplemented with the 9-item
      Patient Health Questionnaire (PHQ-9). Final determination for eligibility will be made by the
      study clinician. Only participants with a suboptimal outcome to a well documented, adequately
      delivered (dose and duration), trial with selective serotonin reuptake inhibitor (SSRI) or a
      serotonin and norepinephrine reuptake inhibitor (SNRI) or mirtazapine will be eligible for
      the study. Failure to achieve an adequate outcome will be ascertained by a score on the
      16-item Quick Inventory of Depressive Symptomatology - Clinician rated (QIDS-C16) scale &gt;= 16
      (considered severe depression) after at least 6 weeks of treatment or QIDS-C16 &gt;= 11
      (considered moderately severe depression) after at least 8 weeks of treatment. Otherwise, the
      inclusion criteria are broad and the exclusion criteria are few; participants with most
      comorbid general medical or psychiatric disorders are generally included to provide a broadly
      representative sample.

      Participants will be randomized (1:1:1 ratio) to switch to bupropion-SR alone (n=506),
      current antidepressant plus bupropion-SR (n=506), or current antidepressant plus aripiprazole
      (n=506). Treatment will be guided by clinician-rated symptom measures (the PHQ-9) and global
      side effects measures (the Frequency, Intensity, and Burden of Side Effects Rating or FIBSER)
      obtained at each treatment visit. Acute treatment visits will occur at baseline and at weeks
      1, 2, 4, 6, 8, 10, and 12 to ensure delivery of appropriate and yet vigorous and tolerable
      pharmacotherapy. Participants who tolerate the acute treatment and achieve adequate response
      at 12 weeks will enter the 24-week Continuation Treatment phase, during which the initial
      treatment will continue and visits will occur every four weeks subsequently until patients
      have been followed for 36 weeks post-randomization. The QIDS-C16 will be administered at
      baseline and at each follow-up visit by an independent evaluator (who will be blinded to
      treatment assignment) to measure symptoms of depression for the study outcomes of remission,
      response and relapse. Neither the participant nor the treating clinician will be blinded to
      treatment.

      Primary hypotheses:

      Primary hypothesis 1.a: Remission rate from major depressive disorder will be higher in
      patients whose treatment is augmented with bupropion-SR (antidepressant + bupropion-SR)
      compared to those switched to bupropion-SR monotherapy.

      Primary Hypothesis 1.b: Remission rate from major depressive disorder will be higher in
      patients whose treatment is augmented with aripiprazole (antidepressant + aripiprazole)
      compared to those switched to bupropion-SR monotherapy.

      Secondary hypotheses:

      Secondary Hypothesis 2.a: Remission rate will be greater in patients whose treatment is
      augmented with bupropion-SR (antidepressant + bupropion-SR) than in those augmented with
      aripiprazole (antidepressant + aripiprazole).

      Secondary Hypothesis 2.b: Relapse rate (within 36 weeks of the initiation of treatment) will
      be lower in patients whose antidepressant is augmented with bupropion-SR (antidepressant +
      bupropion-SR) than in those whose antidepressant is switched to bupropion-SR monotherapy.

      Secondary Hypothesis 2.c: Relapse rate (within 36 weeks of the initiation of treatment) will
      be lower in patients whose treatment is augmented with aripiprazole (antidepressant +
      aripiprazole) vs. those switched to bupropion-SR monotherapy.

      Secondary Hypothesis 2.d: Relapse rate (within 36 weeks of the initiation of treatment) will
      be lower in patients whose treatment is augmented with bupropion-SR (antidepressant +
      bupropion-SR) than in patients whose treatment was augmented with aripiprazole
      (antidepressant + aripiprazole).

      Secondary Hypothesis 2.e: The proportion of patients who develop akathisia, other
      akathisia-like side effects (e.g., tremor, irritability, motor restlessness) and
      extrapyramidal side effects will be greater in the patients whose antidepressant treatment is
      augmented with aripiprazole (antidepressant + aripiprazole) compared to patients whose
      treatment is augmented with bupropion-SR (antidepressant + bupropion-SR), or switched to
      bupropion-SR monotherapy.

      Secondary Hypothesis 2.f: The relative costs (direct and indirect) of augmenting an
      antidepressant with aripiprazole (antidepressant + aripiprazole) will be greater than the
      costs of antidepressant augmentation with bupropion-SR (antidepressant + bupropion-SR), and
      the costs of antidepressant augmentation with bupropion-SR (antidepressant + bupropion-SR)
      will be greater than the costs of switching to bupropion-SR monotherapy, and augmentation and
      monotherapy with bupropion-SR will be more cost-effective than aripiprazole augmentation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Protocol Remission of Symptoms of Major Depressive Disorder</measure>
    <time_frame>During acute phase (12 weeks)</time_frame>
    <description>Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of &lt;= 5 for two consecutive visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase</measure>
    <time_frame>Within 36 weeks after randomization (initiation of treatment)</time_frame>
    <description>Relapse in symptoms of major depression defined as a QIDS-C16 =&gt; 11 among those achieving remission in the acute phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Protocol Response as Reduction in Symptoms of Major Depression (&gt;= 50% Reduction in QIDS-C)</measure>
    <time_frame>During acute phase (up to 12 weeks)</time_frame>
    <description>Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale</measure>
    <time_frame>During acute phase (up to 12 weeks)</time_frame>
    <description>Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1522</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Switching: Bupropion-SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switching: Bupropion-SR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmenting: Antidepressant + Bupropion-SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmenting: Antidepressant + Bupropion-SR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmenting: Antidepressant + Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmenting: Antidepressant + Aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switching: Bupropion-SR</intervention_name>
    <description>Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
    <arm_group_label>Switching: Bupropion-SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmenting: Antidepressant + Bupropion-SR</intervention_name>
    <description>Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
    <arm_group_label>Augmenting: Antidepressant + Bupropion-SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmenting: Antidepressant + Aripiprazole</intervention_name>
    <description>Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
    <arm_group_label>Augmenting: Antidepressant + Aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of single or recurrent, non-psychotic, major depressive disorder

          -  Currently taking a selective serotonin reuptake inhibitor (SSRI) or
             serotonin-norepinephrine reuptake inhibitor (SNRI) or mirtazapine for major depressive
             disorder

          -  Need for &quot;next-step&quot; treatment based on documented suboptimal outcome from current
             antidepressant treatment for major depressive episode (at least 6 weeks treatment with
             a QIDS-C16 &gt;= 16 or at least 8 weeks with a QIDS-C16 &gt;= 11; and at least 3 weeks at a
             stable &quot;optimal&quot; dose

          -  Age: 18 years of age or older

        Exclusion Criteria:

          -  Prior inadequate response after an adequate treatment trial or clear cut intolerance
             to either of the study medications (aripiprazole or bupropion)

          -  Current treatment with bupropion, aripiprazole or any other antipsychotic agent

          -  Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or
             psychosis not otherwise specified

          -  Current diagnosis of Dementia

          -  Current diagnosis of an eating disorder or a seizure disorder

          -  High suicide risk currently requiring acute intervention (other than outpatient
             treatment of depression)

          -  Unstable, serious medical condition or one requiring acute medical treatment, or
             anticipation of hospitalization for extended care

          -  Requiring immediate hospitalization for psychiatric disorders

          -  Physiologic substance dependence requiring detoxification (excluding nicotine) in the
             past 30 days (substance abuse is not an exclusion criteria)

          -  Taking any concomitant medication that contraindicates any of treatment options or
             augmenting agents known to have an antidepressant effect

          -  Concurrent or recent participation (within the last 30 days) in another conflicting
             clinical trial with a mental health, investigational drug, or medical device
             intervention

          -  Female - pregnant or lactating or planning to become pregnant

          -  Patient was not able or willing to provide informed consent; or changed mind about
             participating prior to randomization

          -  Patient was not referred to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Somaia Mohamed, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sidney Zisook, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA San Diego Healthcare System, San Diego, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuscaloosa VA Medical Center, Tuscaloosa, AL</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix VA Health Care System, Phoenix, AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System, Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System, Loma Linda, CA</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System, Long Beach, CA</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center, Washington, DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital, Tampa, FL</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard L. Roudebush VA Medical Center, Indianapolis, IN</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center, Kansas City, MO</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis VA Medical Center John Cochran Division, St. Louis, MO</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico VA Health Care System, Albuquerque, NM</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108-5153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville VA Medical Center, Asheville, NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center, Cincinnati, OH</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Stokes VA Medical Center, Cleveland, OH</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis VA Medical Center, Memphis, TN</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System, Temple, TX</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center, Salem, VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System American Lake Division, Tacoma, WA</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarksburg Louis A. Johnson VA Medical Center, Clarksburg, WV</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William S. Middleton Memorial Veterans Hospital, Madison, WI</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center, Milwaukee, WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Res. 2015 Oct 30;229(3):760-70. doi: 10.1016/j.psychres.2015.08.005. Epub 2015 Aug 6.</citation>
    <PMID>26279130</PMID>
  </reference>
  <results_reference>
    <citation>Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require &quot;next-step&quot; treatments: A VAST-D report. J Affect Disord. 2016 Dec;206:232-240. doi: 10.1016/j.jad.2016.07.023. Epub 2016 Jul 26.</citation>
    <PMID>27479536</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S; and the VAST-D Investigators, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11;318(2):132-145. doi: 10.1001/jama.2017.8036.</citation>
    <PMID>28697253</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>April 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2018</results_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mood Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Depressive Disorder</keyword>
  <keyword>Depressive Disorder, Major</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Remission</keyword>
  <keyword>Relapse</keyword>
  <keyword>Cost-Effectiveness</keyword>
  <keyword>Atypical Antipsychotic</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Augmentation</keyword>
  <keyword>Veterans</keyword>
  <keyword>Mental Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Switching: Bupropion-SR</title>
          <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="P2">
          <title>Augmenting: Antidepressant + Bupropion-SR</title>
          <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="P3">
          <title>Augmenting: Antidepressant + Aripiprazole</title>
          <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Acute Treatment Phase (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="511"/>
                <participants group_id="P2" count="506"/>
                <participants group_id="P3" count="505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="378"/>
                <participants group_id="P3" count="406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dure to other illness</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved away</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason for withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed to Week 12 But Then Withdrawn</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="378"/>
                <participants group_id="P3" count="406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>QIDS Score &gt;=11</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to Other Illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved Away</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Oher reason for withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>End of Study Time</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Continuation of Treatment (Week 12 - 36)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>End of Study Time</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved away</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to Other Illness</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason for withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The ASEX (female) version of the questionnaire was specific to females.The ASEX (male) version of the questionnaire was specific to males. Not all females or males completed the questionnaire, therefore, the number of responders is lower than number of participants due to missing responses.</population>
      <group_list>
        <group group_id="B1">
          <title>Switching: Bupropion-SR</title>
          <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="B2">
          <title>Augmenting: Antidepressant + Bupropion-SR</title>
          <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="B3">
          <title>Augmenting: Antidepressant + Aripiprazole</title>
          <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="511"/>
            <count group_id="B2" value="506"/>
            <count group_id="B3" value="505"/>
            <count group_id="B4" value="1522"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="12.2"/>
                    <measurement group_id="B2" value="54.4" spread="12.2"/>
                    <measurement group_id="B3" value="54.2" spread="12.3"/>
                    <measurement group_id="B4" value="54.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                    <measurement group_id="B2" value="425"/>
                    <measurement group_id="B3" value="428"/>
                    <measurement group_id="B4" value="1296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="454"/>
                    <measurement group_id="B2" value="449"/>
                    <measurement group_id="B3" value="459"/>
                    <measurement group_id="B4" value="1362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="338"/>
                    <measurement group_id="B4" value="1022"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QIDS-C16 Score</title>
          <description>Quick Inventory of Depression Symptomatology - Clinician rated (QIDS-C16) score: summary score of severity of depression symptoms. (range: 0 [better],27 [worse]), www.ids-qids.org</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.6" spread="3.3"/>
                    <measurement group_id="B2" value="16.6" spread="3.2"/>
                    <measurement group_id="B3" value="16.9" spread="3.3"/>
                    <measurement group_id="B4" value="16.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Health Questionnaire (PHQ-9)</title>
          <description>Patient Health Questionnaire (PHQ-9) score is a standard assessment of severity of depression symptoms. (range: 0 [better], 27 [worse]). http://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/patient-health.aspx</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.9" spread="5.2"/>
                    <measurement group_id="B2" value="16.3" spread="5.2"/>
                    <measurement group_id="B3" value="16.3" spread="5.2"/>
                    <measurement group_id="B4" value="16.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI - Severity Score</title>
          <description>Clinical Global Impression (CGI) - Severity score - standard questionnaire for severity of depression symptoms (range: 1 [less severe],7 [more severe]), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880930/</description>
          <population>Assessments missing for two participants at baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="510"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1520"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="1.0"/>
                    <measurement group_id="B2" value="4.6" spread="0.9"/>
                    <measurement group_id="B3" value="4.6" spread="1.0"/>
                    <measurement group_id="B4" value="4.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck Anxiety Inventory</title>
          <description>Beck Anxiety Inventory (BAI) - This is a standard questionnaire to assess anxiety of participant. The mean and standard deviation of the total score (range: 0 [low anxiety - better], 63 [higher anxiety - worse] ), https://www.beckinstitute.org/get-informed/tools-and-resources/professionals/patient-assessment-tools/</description>
          <population>Assessment missing for three participants at baseline</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="510"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="503"/>
                    <count group_id="B4" value="1519"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="11.1"/>
                    <measurement group_id="B2" value="19.0" spread="11.4"/>
                    <measurement group_id="B3" value="19.7" spread="11.3"/>
                    <measurement group_id="B4" value="19.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arizona Sexual Experiences Scale (Female)</title>
          <description>This is a standard questionnaire for quantification of sexual dysfunction. The mean and standard deviation of the total score are presented here (range 5-30; 5 indicates better experiences, 30 indicates worse experiences) - this version is specific to females.</description>
          <population>The ASEX (female) version of the questionnaire was specific to females. Not all females completed the questionnaire, therefore, the number of responders is lower than number of female participants due to missing responses.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="64"/>
                    <count group_id="B2" value="76"/>
                    <count group_id="B3" value="73"/>
                    <count group_id="B4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="1.1"/>
                    <measurement group_id="B2" value="4.2" spread="1.1"/>
                    <measurement group_id="B3" value="4.2" spread="1.2"/>
                    <measurement group_id="B4" value="4.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arizona Sexual Experiences Scale (male)</title>
          <description>This is a standard questionnaire for quantification of sexual dysfunction. Mean and standard deviation of total score are presented here (range 5-30; 5 indicates better experiences, 30 indicates worse experiences) - this version specific to males. Not all males completed the questionnaire, number of responders is lower than number of males due to missing responses.</description>
          <population>The ASEX (male) version of the questionnaire was specific to males. Not all males completed the questionnaire, therefore, the number of responders is lower than number of male participants due to missing responses.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="434"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="421"/>
                    <count group_id="B4" value="1273"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.1"/>
                    <measurement group_id="B2" value="4.1" spread="1.1"/>
                    <measurement group_id="B3" value="4.1" spread="1.2"/>
                    <measurement group_id="B4" value="4.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTSD</title>
          <description>Post-traumatic stress disorder (PTSD) determined by PTSD panel on MINI International Neuropsychiatric Interview (MINI) V6.0.0 following the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, administered prior to randomization - current diagnosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="225"/>
                    <measurement group_id="B4" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroQol Health State Score</title>
          <description>General health-related quality of life (range 0 - 100; 0 indicates worse health state, 100 indicates best possible health state)</description>
          <population>Assessment missing for one participant at baseline</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="505"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1521"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="20.5"/>
                    <measurement group_id="B2" value="52.7" spread="19.8"/>
                    <measurement group_id="B3" value="54.0" spread="20.8"/>
                    <measurement group_id="B4" value="53.8" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Score</title>
          <description>Quality of Life Enjoyment and Satisfaction (Q_LES_Q) Score - adjusted for percent of maximum score - measures general quality of life (percent of raw score ranges 0 - 100; 0 indicates worse quality, 100 indicates best quality)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="13.8"/>
                    <measurement group_id="B2" value="40.3" spread="14.8"/>
                    <measurement group_id="B3" value="40.1" spread="14.8"/>
                    <measurement group_id="B4" value="40.6" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cumulative Illness Rating Scale (CIRS) Severity Index</title>
          <description>Standard questionnaire to assess comorbidities (range 0-56; 0 indicates least comorbidities [none], 56 greatest severity of comorbidities)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="511"/>
                    <count group_id="B2" value="506"/>
                    <count group_id="B3" value="505"/>
                    <count group_id="B4" value="1522"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="5.5"/>
                    <measurement group_id="B2" value="11.1" spread="4.9"/>
                    <measurement group_id="B3" value="11.0" spread="5.1"/>
                    <measurement group_id="B4" value="11.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Protocol Remission of Symptoms of Major Depressive Disorder</title>
        <description>Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of &lt;= 5 for two consecutive visits.</description>
        <time_frame>During acute phase (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switching: Bupropion-SR</title>
            <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O2">
            <title>Augmenting: Antidepressant + Bupropion-SR</title>
            <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O3">
            <title>Augmenting: Antidepressant + Aripiprazole</title>
            <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Protocol Remission of Symptoms of Major Depressive Disorder</title>
          <description>Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of &lt;= 5 for two consecutive visits.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>Co-primary hypothesis: After ordering results from largest p-value to smallest (Hochberg approach) the comparison of Augmenting Antidepressant+Bupropion with Switching to Bupropion-SR was performed at the 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>Represents relative odds of remission for Augmentation Antidepressant + Bupropion-SR / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Co-primary hypothesis: After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Aripiprazole with Switching to Bupropion-SR was performed at the 0.025 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Co-primary hypothesis: Second ordered test after ordering largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Aripiprazole with Switching to Bupropion-SR was performed at the 0.025 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>Represents relative odds of remission for Augmentation Antidepressant + Aripiprazole / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>If either if the first two hypothesis tests for the co-primary hypotheses were significant, perform the test of Augmentation Antidepressant + Aripiprazole vs. Augmentation Antidepressant + Bupropion-SR at the 0.05 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>Following the gate-keeping strategy of the analysis plan, complete the comparison of Augmentation Antidepressant + Aripiprazole vs. Augmentation Antidepressant + Bupropion-SR was evaluated at the 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Represents relative odds of remission for Augmentation Antidepressant + Aripiprazole / Augmentation Antidepressant + Bupropion-SR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase</title>
        <description>Relapse in symptoms of major depression defined as a QIDS-C16 =&gt; 11 among those achieving remission in the acute phase.</description>
        <time_frame>Within 36 weeks after randomization (initiation of treatment)</time_frame>
        <population>The Analysis Population is the cohort of participants who met the criteria for protocol remission during the Acute Phase (first 12 Weeks of follow-up)</population>
        <group_list>
          <group group_id="O1">
            <title>Switching: Bupropion-SR</title>
            <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O2">
            <title>Augmenting: Antidepressant + Bupropion-SR</title>
            <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O3">
            <title>Augmenting: Antidepressant + Aripiprazole</title>
            <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase</title>
          <description>Relapse in symptoms of major depression defined as a QIDS-C16 =&gt; 11 among those achieving remission in the acute phase.</description>
          <population>The Analysis Population is the cohort of participants who met the criteria for protocol remission during the Acute Phase (first 12 Weeks of follow-up)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>Represents relative odds of relapse for Augmentation Antidepressant + Bupropion-SR / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>Represents relative odds of relapse for Augmentation Antidepressant + Aripiprazole / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>Represents relative odds of relapse for Augmentation Antidepressant + Aripiprazole / Augmentation Antidepressant + Bupropion-SR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Protocol Response as Reduction in Symptoms of Major Depression (&gt;= 50% Reduction in QIDS-C)</title>
        <description>Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater</description>
        <time_frame>During acute phase (up to 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Switching: Bupropion-SR</title>
            <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O2">
            <title>Augmenting: Antidepressant + Bupropion-SR</title>
            <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O3">
            <title>Augmenting: Antidepressant + Aripiprazole</title>
            <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Protocol Response as Reduction in Symptoms of Major Depression (&gt;= 50% Reduction in QIDS-C)</title>
          <description>Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="332"/>
                    <measurement group_id="O3" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Bupropion with Switching to Bupropion was performed at the 0.05 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Bupropion / Switching to Bupropion</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Aripiprazole with Switching to Bupropion-SR was performed at the 0.025 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center (site)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Aripiprazole / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Following the gate-keeping strategy of the analysis plan, complete the comparison of Augmentation Antidepressant + Aripiprazole with Augmentation Antidepressant + Bupropion-SR at the 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Aripiprazole / Augmentation Antidepressant + Bupropion-SR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale</title>
        <description>Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved).</description>
        <time_frame>During acute phase (up to 12 weeks)</time_frame>
        <population>Whole randomized cohort by intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Switching: Bupropion-SR</title>
            <description>Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O2">
            <title>Augmenting: Antidepressant + Bupropion-SR</title>
            <description>Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
          <group group_id="O3">
            <title>Augmenting: Antidepressant + Aripiprazole</title>
            <description>Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale</title>
          <description>Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved).</description>
          <population>Whole randomized cohort by intent-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="376"/>
                    <measurement group_id="O3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Bupropion with Switching to Bupropion was performed at the 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Bupropion / Switching to Bupropion</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>After ordering results form largest p-value to smallest (Hochberg approach) the comparison of Augmentation Antidepressant + Aripiprazole with Switching to Bupropion-SR was performed at the 0.025 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Stratified by participating medical center</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Aripiprazole / Switching to Bupropion-SR</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>Following the gate-keeping strategy of the analysis plan, complete the comparison of Augmentation Antidepressant + Aripiprazole with Augmentation Antidepressant + Bupropion-SR at the 0.05 significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>Represents relative odds of response for Augmentation Antidepressant + Aripiprazole / Augmentation Antidepressant + Bupropion-SR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected from the time of enrollment to withdrawal (up to 36 weeks after randomization) with one month of surveillance after withdrawal. Non-serious adverse events were collected from the time of randomization to withdrawal (up to 36 weeks after randomization).</time_frame>
      <desc>A non-serious adverse events was reported if it was among the symptoms prompted for at each scheduled follow-up or if it was a symptom assessed as possibly related to s study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Switching: Bupropion-SR</title>
          <description>Switching: Bupropion-SR
Switching: Bupropion-SR: Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="E2">
          <title>Augmenting: Antidepressant + Bupropion-SR</title>
          <description>Augmenting: Antidepressant + Bupropion-SR
Augmenting: Antidepressant + Bupropion-SR: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
        <group group_id="E3">
          <title>Augmenting: Antidepressant + Aripiprazole</title>
          <description>Augmenting: Antidepressant + Aripiprazole
Augmenting: Antidepressant + Aripiprazole: Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="511"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="511"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="506"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders (total)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="511"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaldosteronism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders (total)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="511"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions (total)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="511"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations (total)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="511"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Infective tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders (total)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="511"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders (total)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="511"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="506"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Somatisation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="511"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Drug detoxification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="383" subjects_at_risk="511"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="506"/>
                <counts group_id="E3" subjects_affected="374" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="511"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="511"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="511"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="305" subjects_affected="189" subjects_at_risk="511"/>
                <counts group_id="E2" events="288" subjects_affected="157" subjects_at_risk="506"/>
                <counts group_id="E3" events="230" subjects_affected="147" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="100" subjects_affected="82" subjects_at_risk="511"/>
                <counts group_id="E2" events="97" subjects_affected="73" subjects_at_risk="506"/>
                <counts group_id="E3" events="115" subjects_affected="105" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="511"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="506"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="511"/>
                <counts group_id="E2" events="41" subjects_affected="38" subjects_at_risk="506"/>
                <counts group_id="E3" events="81" subjects_affected="72" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="134" subjects_affected="114" subjects_at_risk="511"/>
                <counts group_id="E2" events="111" subjects_affected="95" subjects_at_risk="506"/>
                <counts group_id="E3" events="142" subjects_affected="113" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="511"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E3" events="20" subjects_affected="17" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="511"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="383" subjects_affected="218" subjects_at_risk="511"/>
                <counts group_id="E2" events="426" subjects_affected="235" subjects_at_risk="506"/>
                <counts group_id="E3" events="433" subjects_affected="239" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="393" subjects_affected="224" subjects_at_risk="511"/>
                <counts group_id="E2" events="349" subjects_affected="200" subjects_at_risk="506"/>
                <counts group_id="E3" events="270" subjects_affected="176" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="511"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="506"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="511"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="506"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="511"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="506"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="63" subjects_affected="50" subjects_at_risk="511"/>
                <counts group_id="E2" events="58" subjects_affected="48" subjects_at_risk="506"/>
                <counts group_id="E3" events="45" subjects_affected="38" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social circumstances</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="511"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="511"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary R. Johnson, MS</name_or_title>
      <organization>VA Cooperative Studies Program Coordinating Center, West Haven, CT</organization>
      <phone>(203) 932-5711 ext 3774</phone>
      <email>gary.johnson4@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

